Virginia Commonwealth University

VCU Scholars Compass
VCU Health Publications

VCU Health

2013

Effect of Daily Chlorhexidine Bathing on HospitalAcquired Infection
Michael W. Climo
Hunter Holmes McGuire Vet Affairs Med Center, Virginia Commonwealth University

Edward S. Wong
Hunter Holmes McGuire Vet Affairs Med Center, Virginia Commonwealth University

Kakotan Sanogo
Virginia Commonwealth University
See next page for additional authors

Follow this and additional works at: http://scholarscompass.vcu.edu/vcuhealth_pubs
Part of the Medicine and Health Sciences Commons
From the New England Journal of Medicine, Climo, M. W., Wong, E. S., Sanogo, K. et al., Effect of Daily Chlorhexidine
Bathing on Hospital-Acquired Infection, Vol. 368, Page 533, Copyright © 2013 Massachusetts Medical Society.
Reprinted with permission.

Downloaded from
http://scholarscompass.vcu.edu/vcuhealth_pubs/10

This Article is brought to you for free and open access by the VCU Health at VCU Scholars Compass. It has been accepted for inclusion in VCU Health
Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.

Authors

Michael W. Climo, Edward S. Wong, Kakotan Sanogo, Deborah S. Yokoe, David K. Warren, Trish M. Perl,
Maureen Bolon, Robert A. Weinstein, Loreen A. Herwaldt, Kent A. Sepkowitz, and John A. Jernigan

This article is available at VCU Scholars Compass: http://scholarscompass.vcu.edu/vcuhealth_pubs/10

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

original article

Effect of Daily Chlorhexidine Bathing
on Hospital-Acquired Infection
Michael W. Climo, M.D., Deborah S. Yokoe, M.D., M.P.H., David K. Warren, M.D.,
Trish M. Perl, M.D., Maureen Bolon, M.D., Loreen A. Herwaldt, M.D.,
Robert A. Weinstein, M.D., Kent A. Sepkowitz, M.D., John A. Jernigan, M.D.,
Kakotan Sanogo, M.S., and Edward S. Wong, M.D.

A BS T R AC T
BACKGROUND

Results of previous single-center, observational studies suggest that daily bathing of
patients with chlorhexidine may prevent hospital-acquired bloodstream infections
and the acquisition of multidrug-resistant organisms (MDROs).
METHODS

We conducted a multicenter, cluster-randomized, nonblinded crossover trial to evaluate the effect of daily bathing with chlorhexidine-impregnated washcloths on the
acquisition of MDROs and the incidence of hospital-acquired bloodstream infections. Nine intensive care and bone marrow transplantation units in six hospitals
were randomly assigned to bathe patients either with no-rinse 2% chlorhexidine–
impregnated washcloths or with nonantimicrobial washcloths for a 6-month period, exchanged for the alternate product during the subsequent 6 months. The incidence rates of acquisition of MDROs and the rates of hospital-acquired bloodstream
infections were compared between the two periods by means of Poisson regression
analysis.
RESULTS

A total of 7727 patients were enrolled during the study. The overall rate of MDRO
acquisition was 5.10 cases per 1000 patient-days with chlorhexidine bathing versus
6.60 cases per 1000 patient-days with nonantimicrobial washcloths (P = 0.03), the
equivalent of a 23% lower rate with chlorhexidine bathing. The overall rate of hospital-acquired bloodstream infections was 4.78 cases per 1000 patient-days with
chlorhexidine bathing versus 6.60 cases per 1000 patient-days with nonantimicrobial washcloths (P = 0.007), a 28% lower rate with chlorhexidine-impregnated washcloths. No serious skin reactions were noted during either study period.
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CONCLUSIONS

Daily bathing with chlorhexidine-impregnated washcloths significantly reduced
the risks of acquisition of MDROs and development of hospital-acquired bloodstream infections. (Funded by the Centers for Disease Control and Prevention and
Sage Products; ClinicalTrials.gov number, NCT00502476.)
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ultidrug-resistant organisms
(MDROs), including methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant enterococcus (VRE), have
become endemic in many acute care and longterm care facilities.1-5 Infections with these organisms are often difficult to treat, owing to a
dwindling armamentarium of active antimicrobial agents. The Centers for Disease Control and
Prevention (CDC) has promulgated a variety of
strategies, including hand hygiene and the use of
isolation precautions, to limit the spread of these
organisms among patients, but these strategies
require consistent adherence to practices by large
numbers of health care personnel during frequent patient encounters and can be difficult to
sustain.6 In addition, health care–associated infections involving these and other microorganisms7,8 are associated with considerable morbidity
and mortality and with substantial excess costs
that, in some cases, are no longer reimbursed by
third-party payers, including the Centers for Medicare and Medicaid Services.9,10
Targeted interventions, particularly in intensive care units (ICUs), can substantially reduce the
risk of hospital-acquired bloodstream infections
associated with the use of central venous catheters. Several large studies have shown that improving catheter-insertion processes, including
standardizing insertion-site antisepsis with the
use of chlorhexidine-containing products, can
decrease the risk of infection.11-13 However, the
use of antiseptic agents for patient bathing is
currently considered controversial.
Chlorhexidine gluconate is an antiseptic agent
that has broad-spectrum activity against many
organisms, including S. aureus and enterococcus
species. Unlike many other antiseptics, chlor
hexidine has residual antibacterial activity, which
may decrease the microbial burden on patients’
skin and prevent secondary environmental contamination. Vernon et al. found that daily bathing with chlorhexidine-impregnated cloths decreased the number of VRE colonies on skin by
2.5 log, as compared with bathing with soap
and water, as well as decreasing VRE contamination of health care workers’ hands by 40%
and environmental surfaces by 30%.14 By controlling the source, these investigators reduced
the rate of acquisition of VRE among patients
by 66%.
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Because hospital-acquired bloodstream infections often result from the ingress of skin organisms into the bloodstream along vascular catheters or other breaks in skin integrity, skin
decontamination could theoretically also decrease
the risk of infection. Bleasdale et al. found that
daily bathing with 2% chlorhexidine–impregnated washcloths reduced the incidence of primary bloodstream infections by 60%.15 Our
previous observational study evaluating bathing
with chlorhexidine in six ICUs showed a 66%
reduction in VRE bacteremia.16 Previous studies
of bathing with chlorhexidine have been primarily single-center, before-and-after, observational
studies, with limited general applicability of results. We therefore conducted a multicenter,
randomized trial to evaluate the usefulness of
bathing with chlorhexidine to reduce the risks of
MDRO acquisition and hospital-acquired bloodstream infection among patients at high risk for
health care–associated infections.

ME THODS
STUDY DESIGN

We performed a cluster-randomized, crossover
study involving patients hospitalized in six ICUs
or bone marrow transplantation units between
August 2007 and February 2009. Units were
randomly assigned to perform daily bathing of
patients with either nonantimicrobial washcloths (Comfort Bath, Sage Products) (control) or
washcloths impregnated with 2% chlorhexidine
gluconate (2% Chlorhexidine Gluconate Cloth
Patient Preoperative Skin Preparation, Sage Products) (intervention) during the initial 6-month
study period, followed by daily bathing with the
alternate product during the second 6-month
period.
Bathing was completed according to the manufacturer’s instructions. In brief, washcloths were
used in sequential order to rinse all body surfaces, with the exception of the face during bathing with the 2% chlorhexidine–impregnated
cloths in order to avoid exposure of the mucous
membranes of the eyes and mouth. There was
no washout period in the transition to the new
product. Infections and MDRO acquisitions were
monitored for 2 days after the transition and
assigned to the previous bathing treatment if
they occurred within that time period.
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The order in which units were assigned to the
control or intervention period was stratified according to unit type and facility. The nine participating units were divided into two groups.
Group 1 (five units) started with bathing with
the chlorhexidine-impregnated washcloths, followed by bathing with nonantimicrobial washcloths. Group 2 (four units) started with bathing
with nonantimicrobial washcloths, followed by
bathing with the chlorhexidine-impregnated washcloths. The investigators and clinical staff were
aware of the use of the control or intervention
bathing product.
Before the study was initiated, nurses were
instructed on the proper techniques for bathing
patients with both washcloth products. Skin-care
products that were not compatible with chlorhexidine were eliminated before the study began.
Nursing personnel monitored patients for skin
reactions and reported them to the investigators,
who graded skin reactions on a scale of 1 to 4
(with higher numbers indicating greater severity)
and determined whether the reactions were attributable to bathing (for details of the assessments and scales, see the Supplementary Appendix, available with the full text of this article at
NEJM.org).
All units performed active surveillance testing
for MRSA and VRE throughout the study period.
Unit staff obtained swabs from the nares (for
MRSA) and perirectal area (for VRE) from patients up to 48 hours after admission to the unit
and on discharge from the unit. The microbiology
laboratory at each institution processed surveillance specimens using either standard culturebased or molecular-based (polymerase chain reaction) identification of MRSA and VRE. All
patients found to be colonized or infected with
MRSA or VRE were placed on contact precautions
once test results became available. Patients with
a history of MRSA or VRE colonization or infection were placed on contact precautions at the
time of admission.
Each participating unit submitted at least 10
separate MRSA and VRE isolates obtained from
patients to the coordinating center each month
for chlorhexidine susceptibility testing. Susceptibility testing was completed by means of the
agar dilution method, with chlorhexidine concentrations ranging from 0.1 to 1024.0 μg per
milliliter.17

n engl j med 368;6

STUDY OVERSIGHT

Sage Products supplied the chlorhexidine-impregnated and nonantimicrobial washcloths to participating units for the duration of the study, provided technical and educational support, and
participated in weekly teleconferences with the
study group during the conduct of the study but
was not involved in the study design, the data
analysis, or the preparation of the manuscript.
Approval of the study protocol was obtained from
institutional review boards at the study centers
and the CDC. Waiver of written informed consent
was obtained at each institution, owing to the
minimal-risk nature of the study. Patients who
declined to participate were not bathed with
chlorhexidine-impregnated washcloths. All authors vouch for the completeness and accuracy
of the data presented and for the fidelity of
this report to the study protocol, which is
available at NEJM.org.
DEFINITIONS

Incident and prevalent cases of MRSA or VRE
colonization or infection were classified as previously described.16 Bloodstream infections were
identified with the use of National Healthcare
Safety Network definitions.18 Hospital-acquired
bloodstream infections were defined as bloodstream infections detected more than 48 hours
after admission to the unit. Primary bloodstream
infections were defined as hospital-acquired bloodstream infections detected more than 48 hours
after admission to the unit without an attributable
secondary source of infection. Central-catheter–
associated bloodstream infections were defined
as primary bloodstream infections in patients
with at least one central venous catheter in place
within 48 hours before detection of the infection.
TREATMENT INTERRUPTION

On June 28, 2008, Sage Products initiated a nationwide recall of the 2% chlorhexidine–impregnated
washcloths, because of Burkholderia cepacia contamination of some product lots. Units using the
chlorhexidine product at the time of the recall were
switched to the nonantimicrobial washcloths, and
the institutional review boards were immediately
notified. After remediation and approval by the
institutional review boards, use of the chlorhexidine product was resumed. Data from units that
had been assigned to use the chlorhexidine-based
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Table 1. Characteristics of the Participating Study Units.*

Hospital

Unit

Mean No.
of Monthly
Admissions

Mean No.
of Monthly
Patient-Days

number (range)

Mean Length
of Stay
days

MRSA
Prevalence

VRE
Prevalence

percent of admissions

Baseline Rate of
Primary Bloodstream
Infections†
no./1000 patient-days

Group 1
A

MICU

123.8 (114–142)

C

SICU

46.3 (31–59)

D

SICU 2

51.6 (32–71)

E

CSICU

85.3 (80–100)

F

BMT

41.8 (32–58)

B

MICU

C

MICU–CCU

D
E

692.3 (504–773)

5.6

11.0

21.0

8.1

285.7 (251–314)

6.2

11.4

4.3

9.6

285.7 (227–338)

5.5

4.4

2.8

0

425.9 (375–486)

5.0

6.6

8.3

0.4

786.3 (725–858)

18.8

2.4

21.6

5.5

111.6 (98–126)

598.8 (449–641)

5.4

21.8

21.0

3.1

55.8 (43–73)

299.1 (211–345)

5.4

16.1

9.7

8.5

SICU 1

62.3 (47–76)

316.3 (266–356)

5.1

10.8

8.2

2.2

MICU

72.7 (56–88)

467.1 (404–525)

6.4

23.3

27.9

8.7

Group 2

* Group 1 used chlorhexidine-impregnated washcloths during the first 6-month period and nonantimicrobial washcloths during the second
6-month period, and group 2 did the reverse. BMT denotes bone marrow transplantation unit, CSICU cardiac surgery intensive care unit,
MICU medical intensive care unit, MICU–CCU combined medical intensive care unit and coronary care unit, MRSA methicillin-resistant
Staphylococcus aureus, SICU surgical intensive care unit, and VRE vancomycin-resistant enterococcus.
† The baseline rate of primary bloodstream infections was defined as the number of new cases among eligible patients during the control period.

washcloths during the recall period were cen- stay, rate of use of central venous catheters, mesored from the final analysis.
dian patient age, distribution of patient sex,
monthly rate of incident MRSA colonizations or
STATISTICAL ANALYSIS
infections, monthly rate of incident VRE coloniWe evaluated changes in the mean rates of MRSA zations or infections, rate of prevalent MRSA
and VRE acquisition and hospital-acquired blood- colonization or infection at the time of admisstream infections. We tested the null hypothesis sion, and rate of prevalent VRE colonization or
that the rates during the control period equaled infection at the time of admission. We compared
the rates during the intervention period, using the changes in the rates of incident primary bloodPROC GENMOD procedure in SAS software, ver- stream infections between the control period
sion 8.2 (SAS Institute), to fit a Poisson regression and the intervention period. Continuous varimodel that accounted for monthly prevalence of ables were examined with the use of two-sample
MRSA and VRE colonizations or infections in t-tests and linear regression modeling, and cateach unit as possible confounders.
egorical variables were examined by means of
We used a Cox proportional-hazards regression Fisher’s exact test.
model to compare the time from admission until
the first primary bloodstream infection between
R E SULT S
the control and intervention periods. We calculated the survival time as the interval between CHARACTERISTICS OF THE STUDY UNITS
admission and discharge from the study unit for Twelve units from seven hospitals were recruited
those patients who did not acquire a primary to participate in the planned 12-month study. One
bloodstream infection and as the interval between unit withdrew from the study, and two units were
admission and the first positive culture for pa- eliminated from the analysis because of low comtients with a primary bloodstream infection.
pliance with the study protocol. The final nine
We examined the effect of the following unit study units included medical, coronary care, surcharacteristics on the rates of primary bloodstream gical, and cardiac surgery ICUs and one bone marinfections: unit size, unit type, mean length of row transplantation unit (Table 1). Only 8 (0.1%)
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Table 2. Incidence of Hospital-Acquired Bloodstream Infections and Acquisition of Multidrug Resistant Organisms
(MDROs), MRSA, and VRE.*
Variable

Intervention Period

Control Period

P Value

No. of admissions

3970

3842

0.32

Total days of care

24,902

24,983

0.85

Central-catheter use (days)

13,425

13,049

0.14

Mean length of stay (days)

6.4

6.4

0.53

MRSA prevalence (%)

13.8

12.8

0.14

VRE prevalence (%)

16.3

15.1

0.24

MDRO acquisition
No. of infections
Incidence rate (no./1000 patient-days)

127
5.10

165
6.60

0.03

VRE acquisition
No. of infections
Incidence rate (no./1000 patient-days)

80
3.21

107
4.28

0.05

MRSA acquisition
No. of infections
Incidence rate (no./1000 patient-days)

47
1.89

58
2.32

0.29

Hospital-acquired bloodstream infection
No. of infections
Incidence rate (no./1000 patient-days)

119
4.78

165
6.60

0.007

Primary bloodstream infection
No. of infections
Incidence rate (no./1000 patient-days)

90
3.61

131
5.24

0.006

Central-catheter–associated bloodstream infection
No. of infections
Incidence rate (no./1000 catheter-days)

21
1.55

43
3.30

0.004

29
1.20

34
1.40

0.45

Secondary bloodstream infection
No. of infections
Incidence rate (no./1000 patient-days)

* Prevalence was defined as the total number of prevalent cases per 100 patients admitted to the study unit. The incidence rate was defined as the total number of acquired cases among eligible patients.

of 7735 patients admitted to the participating
units declined to participate in the study, and data
from all 7727 patients who agreed to participate
were included in an intention-to-treat analysis.
ACQUISITION OF MRSA AND VRE

During the control period, when nonantimicrobial
cloths were used, 165 new cases of MRSA or VRE
acquisition were detected, as compared with 127
during the periods of bathing with chlorhexidine.
The overall rate of MRSA or VRE acquisition was
23% lower during the intervention period (5.10 vs.

n engl j med 368;6

6.60 cases per 1000 patient-days, P = 0.03) (Table 2).
Reductions in the incidence of VRE and MRSA acquisition were unrelated to the monthly prevalence
of either MRSA or VRE colonization or infection.
The overall rate of VRE acquisition was 25%
lower during the intervention period than during
the control period (3.21 vs. 4.28 cases per 1000
patient-days, P = 0.05). The overall rate of MRSA
acquisition was 19% lower during the intervention period than during the control period, but this
difference was not significant (1.89 vs. 2.32 cases
per 1000 patient-days, P = 0.29).

nejm.org

february 7, 2013

537

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 13, 2015. For personal use only. No other uses without permission.
Copyright © 2013 Massachusetts Medical Society. All rights reserved.

Cumulative Probability of Primary BSI

The

1.0

0.25

0.9

0.20

0.8

Control

0.15

0.7
0.6

0.10

0.5

0.05

0.4

0.00

0.3

n e w e ng l a n d j o u r na l

Chlorhexidine

0

5

10 15 20 25 30 35 40

0.2
0.1
0.0

P=0.02
0

5

10

15

20

25

30

35

40

Days
No. at Risk
Control
Chlorhexidine

1398
1410

582
616

346
391

218
242

143
151

94
95

59
60

37
36

33
26

55
44

80
64

101
73

114
75

119
80

122
83

127
84

Total Cumulative No.
of Primary BSIs
Control
Chlorhexidine

Figure 1. Kaplan–Meier Estimates of Time to Primary Bloodstream Infection.
The cumulative probability of a primary bloodstream infection (BSI) is
shown for patients who were bathed with chlorhexidine-impregnated washcloths as compared with those who were bathed with nonantimicrobial
washcloths. The overall protective efficacy of chlorhexidine bathing was
30%. The inset shows a more detailed version of the larger graph, with a
cumulative probability of primary BSI of up to 0.25.

BLOODSTREAM INFECTIONS

Overall, 165 hospital-acquired bloodstream infections were detected in patients during the
control period, as compared with 119 during the
intervention period. The rate of hospital-acquired
bloodstream infections was 28% lower during the
intervention period than during the control period
(4.78 vs. 6.60 cases per 1000 patient-days, P = 0.007)
(Table 2). This finding reflected the 31% lower
rate of primary bloodstream infections during the
intervention period, as compared with the control
period (3.61 vs. 5.24 cases per 1000 patient-days,
P = 0.006). The rate of central-catheter–associated
bloodstream infections was 53% lower during the
intervention period than during the control period (1.55 vs. 3.30 cases per 1000 catheter-days,
P = 0.004). The rate of secondary bloodstream infections did not differ significantly between the
intervention and control periods.
On the basis of the Cox proportional-hazards
survival regression analysis, the risk of acquiring a
538
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primary bloodstream infection was significantly
lower among patients bathed with chlorhexidine
than among those bathed with the nonantimicrobial cloths (P = 0.02) (Fig. 1). This effect was
greater among patients with a longer length of
stay in the unit. Among patients who were in the
unit for more than 7 days, the relative risk of a
primary bloodstream infection was 0.69 (95% confidence interval [CI], 0.47 to 0.99) for patients
bathed with chlorhexidine as compared with those
bathed with the nonantimicrobial washcloths.
Among patients who were in the unit for more
than 14 days, the relative risk of a primary bloodstream infection was 0.51 (95% CI, 0.30 to 0.87)
among patients bathed with chlorhexidine as compared with those who were bathed with the nonantimicrobial washcloths.
Among the 221 primary bloodstream infections, the most common pathogens were staphylococci (30%), gram-negative bacilli (23%), enterococci (20%), and fungi (13%) (Table 3). The
incidence rate of primary bloodstream infection
caused by coagulase-negative staphylococci was
56% lower during the intervention period than
during the control period (0.60 vs. 1.36 cases per
1000 patient-days, P = 0.008). Similarly, the incidence rate of primary bloodstream infection
caused by fungi was 53% lower during the intervention period than during the control period,
but this finding was not significant (0.36 vs.
0.76 cases per 1000 patient-days, P = 0.06).
The incidence of central-catheter–associated
bloodstream infections was significantly lower
during the intervention period than during the
control period for infections involving grampositive organisms (0.89 vs. 1.76 cases per 1000
catheter-days, P = 0.05) and those involving fungi
(0.07 vs. 0.77 cases per 1000 catheter-days,
P<0.001). Overall, the incidence of central-catheter–associated fungal bloodstream infection was
90% lower during the intervention period than
during the control period. Bathing with chlorhexidine was not associated with a significant reduction in the incidence of central-catheter–associated
bloodstream infections involving gram-negative
organisms or those involving VRE or MRSA, findings that are probably related to the low number
of infections caused by these organisms.
Owing to concern that the interruption of treatment may have affected the observed outcomes,
we performed an additional analysis of the incidence rates of bloodstream infections that in-
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Table 3. Etiologic Agents of Identified Primary Bloodstream Infections.*
Agent

Intervention Period

Staphylococci
Staphylococcus aureus
Coagulase-negative staphylococci
Enterococci
Enterococcus faecalis

Control Period

P Value

No. of
Infections

Incidence Rate

No. of
Infections

24

0.96

42

1.68

0.03

9

0.36

8

0.32

0.80

15

0.60

34

1.36

0.008

19

0.76

26

1.04

0.30

13

0.52

19

0.76

0.29

Incidence Rate

6

0.24

6

0.24

1.00

23

0.92

27

1.08

0.58

Acinetobacter

1

0.04

2

0.08

1.00

Escherichia

8

0.32

6

0.24

0.52

Enterobacter

2

0.08

8

0.32

0.06

Klebsiella

5

0.20

5

0.20

1.00

Pseudomonas

4

0.16

2

0.08

0.41

Serratia

2

0.08

1

0.04

1.00

Stenotrophomonas

0

0.00

1

0.04

1.00

Other

1

0.04

2

0.08

1.00

E. faecium
Gram-negative bacilli

Fungi

9

0.36

19

0.76

0.06

Candida

7

0.28

16

0.64

0.06

Other

2

0.08

3

0.12

0.66

9

0.36

12

0.48

0.52

Other

6

0.24

5

0.20

0.76

Total

90

3.61

131

5.24

0.01

Polymicrobial organisms

* The incidence rate was defined as the number of primary bloodstream infections per 1000 patient-days.

cluded those months when nonantimicrobial
cloths were used by units affected by the national
recall. The addition of data obtained during the
4 months of treatment interruption, when only
nonantimicrobial bathing cloths were used, did
not alter the analysis results. In this analysis, 58
months of use of nonantimicrobial cloths for
bathing was compared with 54 months of use of
the 2% chlorhexidine-impregnated cloths. The
overall results remained the same. The overall
incidence of hospital-acquired bloodstream infection was decreased in those months when
chlorhexidine was in use, as compared with the
use of the nonantimicrobial washcloths (4.78 vs.
6.32 cases per 1000 patient-days, P = 0.02).

cal ICUs was 40% lower during the intervention
period than during the control period (3.98 vs.
6.62 cases per 1000 patient-days). In contrast, the
rate of primary bloodstream infections in other
units was 17% lower during the intervention period than during the control period (3.10 vs. 3.73
cases per 1000 patient-days) (Fig. 2). However, the
observed reductions in the rate of primary bloodstream infections among medical ICUs were not
significantly associated with the unit type. Other
unit characteristics — unit size, mean length of
stay, baseline rate of primary bloodstream infections, median age of patients, MRSA and VRE
prevalence, catheter use, and sex distribution —
were not associated with changes in the rates of
primary bloodstream infections.

UNIT CHARACTERISTICS

Reductions in rates of primary bloodstream in- CHLORHEXIDINE SUSCEPTIBILITY
fections were highest among medical ICUs. The We performed antimicrobial susceptibility testrate of primary bloodstream infections in medi- ing on clinical isolates collected during the entire
n engl j med 368;6
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Figure 2. Rates of Primary Bloodstream Infections
According to the Type of Hospital Unit.
Incidence rates of hospital-acquired primary bloodstream infections are shown among units using daily
bathing with either chlorhexidine-impregnated washcloths or nonantimicrobial washcloths (control). BMT
denotes bone marrow transplantation unit, MICU
medical intensive care unit, and SICU surgical intensive care unit.

study period. We tested a total of 1106 isolates
(713 MRSA and 393 VRE) for susceptibility to
chlorhexidine by means of the agar dilution method. Chlorhexidine was slightly more active against
MRSA isolates, with a minimum inhibitory concentration required to inhibit the growth of 90%
of organisms of 4 μg per milliliter, as compared
with 8 μg per milliliter for VRE isolates.
ADVERSE REACTIONS

The overall incidence of skin reactions among
patients assigned to chlorhexidine bathing was
2.0% (78 of 3970 patients), as compared with
3.4% (130 of 3842) among those assigned to
bathing with the control product. All 208 reported skin reactions were considered to be unrelated
to the bathing intervention, and overall, 85% of
the reactions were classified as mild to moderate
(grade 1 or 2).

DISCUSSION
The findings of this multicenter, cluster-randomized study evaluating daily bathing with chlorhexidine support the results of previous single-center
trials suggesting that bathing with chlorhexidine
reduces the transmission of resistant organisms
540
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and the risk of hospital-acquired bloodstream infections among patients in ICUs and bone marrow transplantation units.14-16,19,20 In addition, the
participation of facilities from different geographic regions in the United States supports the generalizability of these results to other academic
medical centers.
Our results support the findings of Vernon et
al. and Bleasdale et al. and suggest that bathing
with chlorhexidine may be particularly effective
in reducing the risk of bloodstream infections
among patients in the ICU.14,15 In contrast to
these previous studies, which involved a limited
number of units, our multicenter design allowed
a more robust examination of whether the reductions in rates of bloodstream infections were
related to the type of unit. We found no significant interaction between the type of unit and the
development of bloodstream infections, suggesting that bathing with chlorhexidine may be
beneficial in many unit settings. In addition,
bathing with chlorhexidine may be particularly
beneficial for patients with long ICU stays.
Our study also had some unanticipated findings. First, as compared with bathing with the
control product, bathing with chlorhexidine was
associated with lower rates of central-catheter–
associated fungal bloodstream infection. Previous studies have shown that bathing with
chlorhexidine is associated with a lower risk of
central-catheter–associated bloodstream infection involving gram-positive cocci,14-16 but reduced rates of fungemia have not been reported.
Chlorhexidine has biphasic fungicidal activity,21
but topical use has not been suggested as a possible intervention to reduce the incidence of fungemia among patients with indwelling central
catheters. Previous efforts to reduce the incidence
of fungemia have relied mostly on systemic antifungal prophylaxis, which can increase the incidence of antifungal resistance among fungal
isolates.22 If our results are confirmed, topical
use of chlorhexidine could be added to strategies
to prevent fungal infections.
Bathing with chlorhexidine was associated
with significant reductions in the incidence of
gram-positive bacteremias, findings that are
similar to the results of previous studies. The
majority of these reductions were related to the
reductions in the incidence of infections involving coagulase-negative staphylococci. Despite
the overall reduction in the acquisition of MRSA
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and VRE, significant reductions in the incidence
of MRSA and VRE bacteremias were not seen.
This was probably related to the overall low number of hospital-acquired bacteremias due to these
two organisms.
We did not identify any serious adverse effects of daily bathing with the chlorhexidineimpregnated washcloths. Serious allergic reactions have been reported with the topical use of
chlorhexidine, but these reactions appear to be
rare.23-26 We did not detect the emergence of
MRSA or VRE isolates with high-level resistance
to chlorhexidine during the study. Concern regarding increased resistance of nosocomial bacteria
to biocides and disinfectants like chlorhexidine
has tempered enthusiasm for wider adoption of
their use in hospitals for skin antisepsis.27-34 The
potential for the emergence of resistance to
chlorhexidine remains a substantial concern and
should be monitored over time.35
Identifying simple, cost-effective, and safe strategies for the prevention of health care–associated
infection is essential. Daily bathing with chlorhex-

idine-impregnated washcloths is a strategy that
is relatively straightforward to implement and
sustain because it does not require a substantial
change from patient-bathing practices that are
currently routine. We found that this intervention
was associated with reductions in the rates of
MRSA and VRE acquisition and hospital-acquired
bloodstream infection.
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